Refine Search

New Search

Result: 1

(searched for: doi:10.32474/oajom.2020.04.000182)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Published: 26 May 2021
by MDPI
Current Oncology, Volume 28, pp 2007-2013; https://doi.org/10.3390/curroncol28030186

Abstract:
The COVID-19 situation is a worldwide health emergency with strong implications in clinical oncology. In this viewpoint, we address two crucial dilemmas from the ethical dimension: (1) Is it ethical to postpone or suspend cancer treatments which offer a statistically significant benefit in quality of life and survival in cancer patients during this time of pandemic?; (2) Should we vaccinate cancer patients against COVID-19 if scientific studies have not included this subgroup of patients? Regarding the first question, the best available evidence applied to the ethical principles of Beauchamp and Childress shows that treatments (such as chemotherapy) with clinical benefit are fair and beneficial. Indeed, the suspension or delay of such treatments should be considered malefic. Regarding the second question, applying the doctrine of double-effect, we show that the potential beneficial effect of vaccines in the population with cancer (or those one that has had cancer) is much higher than the potential adverse effects of these vaccines. In addition, there is no better and less harmful known solution.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top